GlycoNex to Present Preclinical Data on GNX1021 at AACR 2025
Data highlights preclinical efficacy and safety of GNX1021, a novel glycan-targeting ADC, in gastric cancer models
NEW TAIPEI CITY, Taiwan, March 27, 2025 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that preclinical data on GNX1021 will be presented on April 28 at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois.
GNX1021 is an antibody-drug conjugate (ADC) targeting branched Lewis B/Y (bLeB/Y), a unique tumor-associated glycan antigen overexpressed in gastric cancer and other solid tumors. The poster will highlight in vivo efficacy and safety findings from gastric cancer models that demonstrate GNX1021's tumor control activity.
"We are very pleased that research involving GNX1021, our glycan-targeting ADC, was accepted for presentation at AACR 2025," said Dr. Mei-Chun Yang, CEO of GlycoNex. "AACR is one of the most influential oncology meetings in the world, and the opportunity to showcase the potential of GNX1021 to treat gastric cancer, an often-deadly cancer with few available therapies, highlights the importance of this program."
Presentation Details:
Event: | American Association for Cancer Research (AACR) Annual Meeting 2025 |
Session Category: | Experimental and Molecular Therapeutics |
Session: | Growth Factor Receptors and Other Surface Antigens as Targets for Therapy 1 |
Abstract Title: (#2932) | GNX1021, a novel ADC targeting glycans with branched Lewis B/Y, demonstrated preclinical tumor control activity in gastric cancer models and favorable safety |
Date and Time: | April 28, 2025; 2:00 pm CDT |
Location: | McCormick Place Convention Center, Chicago Poster Section 17, Poster Board 6 |
About GlycoNex Inc.
GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing side effects. GlycoNex possesses a robust pipeline led by GNX102, a humanized monoclonal antibody (mAb) designed to target abnormal sugar molecules in cancer cells. GNX102 has successfully completed Phase 1 clinical trials with data demonstrating excellent safety and promising efficacy. GlycoNex is also advancing a portfolio of antibody-drug conjugates (ADCs) that precisely attack cancer cells while sparing healthy tissue. GlycoNex is headquartered in New Taipei City, Taiwan. For more information, visit http://www.glyconex.com.tw.
Contacts for GlycoNex, Inc.
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
[email protected]
Media Relations
Eric Reiss
[email protected]
SOURCE GlycoNex, Inc.
Share this article